Abstract

AIDS: Caution is advised when using the experimental antiretroviral abacavir (1592U89) in the event of a systemic hypersensitivity reaction because continued use may be life-threatening. Glaxo is planning research to determine the cause of the hypersensitivity and is educating physicians, researchers, and volunteers in clinical trials about abacavir hypersensitivity. The Food and Drug Administration (FDA) has been informed as well.